Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Arbutus Biopharma ( (ABUS) ).
On May 21, 2025, Arbutus Biopharma Corporation held its Annual General Meeting of Shareholders, where shareholders elected the company’s director nominees, approved executive compensation, and appointed Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are pivotal for Arbutus Biopharma’s governance and operational transparency, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
Arbutus Biopharma’s overall stock score is weighed down by its weak financial performance and negative valuation outlook. While technical indicators suggest some volatility, the potential for innovative treatments in HBV offers a glimmer of hope. However, executive turnover and legal challenges further contribute to a cautious investment outlook.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The company is engaged in the development of a portfolio of drug candidates with the potential to cure HBV.
Average Trading Volume: 1,073,199
Technical Sentiment Signal: Hold
Current Market Cap: $616.7M
For an in-depth examination of ABUS stock, go to TipRanks’ Stock Analysis page.